Informe sobre el IV Congreso ISKO-España, EOCONSID'99 (Granada,22-24 d'abril de 1999)

El quart EOCONSID (Encuentro de Organización del Conocimiento en Sistemas de Información y Documentación), organitzat per ISKO-España (Capítulo Español de la International Society for Knowledge Organization), ha suposat «situar en el mapa» un congrés i una entitat que fins ara havien tingut poca projecció. Tot i organitzar les trobades regularment ¿cada dos anys¿ des del 1993, el poc coneixement de l'entitat i dels seus objectius comportava una assistència escassa de professionals a les trobades, limitada, es podria dir, als membres de l'entitat i als alumnes de la Universidad Carlos III, ¿entitat que havia acollit les segones i terceres trobades. Igualment, les actes publicades tenien poc ressò, tot i incloure contribucions d'un bon nivell de qualitat. El canvi en els òrgans de govern d'ISKO-España, el 1998, va replantejar la manera d'organitzar el congrés: es va decidir formar un equip independent de la junta directiva que s'hi pogués dedicar plenament i que garantís un major grau de professionalitat.

Informe sobre la I International Conference on Multidisciplinary Information Sciences and Technologies - InSciT2006 (Mèrida, 25, 26, 27 i 28 d'octubre de 2006)

Podeu consultar la versió en castellà a http://hdl.handle.net/2445/8955

Informe sobre la I International Conference on Multidisciplinary Information Sciences and Technologies - InSciT2006 (Mérida, 25, 26, 27 y 28 de octubre de 2006)

Podeu consultar la versió en català a http://hdl.handle.net/2445/8954

International Update, July/August 2010

International news from the Iowa Department of Economic Development

International Update September/October 2010

International News & Events from the Iowa Department of Economic Development

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrine-responsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high.

International Update, November/December 2010

International Business news from the Iowa Department of Economic Development

On some numerical aspects of an active strain model in cardiac mechanics

We are interested in the development, implementation and testing of an orthotropic model for cardiac contraction based on an active strain decomposition. Our model addresses the coupling of a transversely isotropic mechanical description at the cell level, with an orthotropic constitutive law for incompressible tissue at the macroscopic level. The main differences with the active stress model are addressed in detail, and a finite element discretization using Taylor-Hood and MINI elements is proposed and illustrated with numerical examples.

International Update, January-February 2011

International Trade Team news from the Business Development Division of the Iowa Department of Economic Development

The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform.

BACKGROUND: A relative inability to capture a sufficiently large patient population in any one geographic location has traditionally limited research into rare diseases. METHODS AND RESULTS: Clinicians interested in the rare disease lymphangioleiomyomatosis (LAM) have worked with the LAM Treatment Alliance, the MIT Media Lab, and Clozure Associates to cooperate in the design of a state-of-the-art data coordination platform that can be used for clinical trials and other research focused on the global LAM patient population. This platform is a component of a set of web-based resources, including a patient self-report data portal, aimed at accelerating research in rare diseases in a rigorous fashion. CONCLUSIONS: Collaboration between clinicians, researchers, advocacy groups, and patients can create essential community resource infrastructure to accelerate rare disease research. The International LAM Registry is an example of such an effort. 82.